Recent Trends in Local-Regional Recurrence Rates: Implications for Therapeutic Intervention
- 51 Downloads
Purpose of Review
Local and regional recurrences pose a significant therapeutic challenge in the field of breast cancer. Unfortunately, between 5 and 10% of patients will have this form of recurrences. This article seeks to review recent declines in locoregional recurrence risk and discuss the potential implications for the extent of therapeutic intervention currently implemented and how this may change in the future.
Recurrence rates have significantly decreased in recent times. Additionally, the vast amount of clinical research in the field of breast cancer allows for guidelines and traditional treatments to be updated and revamped as novel information is discovered. Patients who had neoadjuvant chemotherapy have been shown to experience a higher rate of recurrence in comparison with patients that had adjuvant chemotherapy. Radiotherapy is now recommended for patients with one to three positive lymph nodes. Axillary resections have been shown to provide no benefits to patients undergoing radiotherapy.
Local and regional recurrence rates are decreasing lately both due to improvements in various therapeutic interventions and in implementation of breast cancer screening so that cancers may be caught earlier. Due to declines in local recurrence risk, it may be reasonable to scale back surgical, chemotherapeutic, and radio-therapeutic interventions.
KeywordsLocal and regional recurrence Breast cancer Radio-therapeutic interventions Chemotherapeutic interventions Breast cancer screening
Compliance With Ethical Standards
Conflict of Interest
The authors declare that they have no competing interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Çelik, V., Aydoğan, T., Yilmaz, M. H., Yaşar, N. F. & Müslümanoğlu, M. Surveillance of patients following primary therapy. in Breast Disease. 2016;447–54. Springer, ChamGoogle Scholar
- 6.Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–97.CrossRefPubMedGoogle Scholar
- 8.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRefGoogle Scholar
- 14.Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast Cancer. J Clin Oncol. 2003;21:976–83.CrossRefPubMedGoogle Scholar
- 22.Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028–37.CrossRefPubMedGoogle Scholar
- 23.Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466–73.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Miles RC, Gullerud RE, Lohse CM, Jakub JW, Degnim AC, Boughey JC. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol. 2012;19:1153.Google Scholar
- 28.•• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39. This recent study reported that neoadjuvant chemotherapy was associated with more frequent local recurrence than adjuvant chemotherapy. CrossRefGoogle Scholar
- 30.• Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis. JAMA. 2017;318:918–26. This study reports on the Z011 trial in which the effects of axillary lymph node dissection was investigated. CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet. Oncol. 2014;15:1303–10.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.•• Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, et al. 21-Gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017;109:djw259. This study reports on the B-28 trial used to study the Oncotype-Dx expression assay. CrossRefPubMedPubMedCentralGoogle Scholar
- 33.•• Cardoso F, van’t Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29. This study reports on the MINDACT trial used to study the Mammaprint recurrence score assay. CrossRefPubMedGoogle Scholar
- 34.Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.• Yao K, Czechura T, Liederbach E, Winchester DJ, Pesce C, Shaikh A, et al. Utilization of accelerated partial breast irradiation for ductal carcinoma in situ, 2003–2011: report from the National Cancer Database. Ann Surg Oncol. 2014;21:3457–65. This study discusses the trends in usage of Accelerated Partial Breast Irradiation and that facility factors were most strongly associated with its use. CrossRefPubMedGoogle Scholar
- 40.• EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35. This study reported that radiotherapy decreases local and regional recurrence rates in the population of patients with one to three positive lymph nodes. CrossRefGoogle Scholar
- 43.Neuman HB, Schumacher JR, Francescatti AB, Adesoye T, Edge SB, Vanness DJ, et al. Risk of synchronous distant recurrence at time of locoregional recurrence in patients with stage II and III breast cancer (AFT-01). J Clin Oncol. JCO2017755389 (2018). https://doi.org/10.1200/JCO.2017.75.5389 (epub ahead of print).
- 47.Wahl AO & Small W Re-irradiation for locally recurrent breast cancer. Medical Radiology. 2016;213–24. Springer, ChamGoogle Scholar
- 48.Ishitobi M, Okumura Y, Nishimura R, Nakatsukasa K, Tanabe M, Yoshida A, et al. Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR. Breast Cancer. 2014;21:754–60.Google Scholar